These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 1532501)

  • 21. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
    Nguyen CV; Bohjanen KA
    Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photochemotherapy (PUVA) in the tumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group.
    Molin L; Thomsen K; Volden G; Groth O
    Acta Derm Venereol; 1981; 61(1):52-4. PubMed ID: 6164215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
    Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
    Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
    [No Abstract]   [Full Text] [Related]  

  • 24. [Chemotherapy of cutaneous T-cell lymphomas with arotinoid].
    Mahrle G; Thiele B; Ippen H
    Dtsch Med Wochenschr; 1983 Nov; 108(46):1753-7. PubMed ID: 6605844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photochemotherapy for mycosis fungoides: long-term followup study.
    Roenigk HH
    Cancer Treat Rep; 1979 Apr; 63(4):669-73. PubMed ID: 445519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of malignant lymphoma of the skin].
    Sterry W
    Dtsch Med Wochenschr; 1988 Feb; 113(6):221-3. PubMed ID: 3276495
    [No Abstract]   [Full Text] [Related]  

  • 28. [Sézary syndrome with ascitis: case report and review of the literature].
    Nubourgh I; Van den Broeck K; Bradstreet C; Praet JP; Cantinieaux B
    Rev Med Brux; 2005; 26(5):445-50. PubMed ID: 16318098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Primary cutaneous lymphoma--mycosis fungoides].
    Nagatani T; Okazawa H; Mizuno H; Yanagi N; Miyazawa M; Baba N
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):23-9. PubMed ID: 9020941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.
    Klein RS; Dunlop JD; Samimi SS; Morrissey KA; Evans KG; Gardner JM; Introcaso CE; Vittorio CC; Rook AH; Micaily B; Kim EJ
    J Am Acad Dermatol; 2013 Jun; 68(6):972-7. PubMed ID: 23415461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
    Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
    Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
    Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
    Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
    Huen AO; Kim EJ
    Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).
    Bunn PA; Hoffman SJ; Norris D; Golitz LE; Aeling JL
    Ann Intern Med; 1994 Oct; 121(8):592-602. PubMed ID: 8085692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
    Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
    J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.